Flanvotumab

Flanvotumab
Monoclonal antibody
Type	Whole antibody
Source	Human
Target	HGF
Clinical data
ATC code	none;
Identifiers
CAS Number	1188277-05-5 ;
ChemSpider	none;
UNII	ZNV4738BS6 ;
Chemical and physical data
Formula	C6470H9986N1714O2018S46
Molar mass	145.5 kg/mol
(what is this?) (verify)

Last updated April 01, 2019

Flanvotumab, also known as IMC-20D7S, is a human monoclonal antibody designed for the treatment of melanoma.^[1] It targets TYRP1.^[2]

Melanoma malignant neoplasm originating from melanocytes

Melanoma, also known as malignant melanoma, is a type of cancer that develops from the pigment-containing cells known as melanocytes. Melanomas typically occur in the skin, but may rarely occur in the mouth, intestines, or eye. In women, they most commonly occur on the legs, while in men they are most common on the back. Sometimes they develop from a mole with changes such as an increase in size, irregular edges, change in color, itchiness, or skin breakdown.

Tyrosinase-related protein 1, also known as TYRP1, is an enzyme which in humans is encoded by the TYRP1 gene.

Flanvotumab was developed by ImClone Systems, now owned by Eli Lilly.^[3]

ImClone Systems Incorporated was a biopharmaceutical company dedicated to developing biologic medicines in the area of oncology. It was founded in 1984 and had its corporate headquarters in Bridgewater, New Jersey and its research headquarters in New York City. On October 6, 2008, it accepted a $6.5 billion acquisition offer from Eli Lilly and Company, and became a fully owned subsidiary of Eli Lilly and Company on November 24, 2008. Prior to the acquisition, it was traded on the NASDAQ stock exchange under the symbol IMCL. Imclone lost its separate identity in 2014 when its former ImClone research and manufacturing sites were renamed Eli Lilly and Company.

Eli Lilly was an American soldier, pharmacist, chemist, and businessman who founded the Eli Lilly and Company pharmaceutical corporation. Lilly enlisted in the Union Army during the American Civil War and recruited a company of men to serve with him in the 18th Independent Battery Indiana Light Artillery. He was later promoted to major and then colonel, and was given command of the 9th Regiment Indiana Cavalry. Lilly was captured in September 1864 and held as a prisoner of war until January 1865. After the war, he attempted to run a plantation in Mississippi, but it failed and he returned to his pharmacy profession after the death of his first wife. Lilly remarried and worked with business partners in several pharmacies in Indiana and Illinois before opening his own business in 1876 in Indianapolis. Lilly's company manufactured drugs and marketed them on a wholesale basis to pharmacies. Lilly's pharmaceutical firm proved to be successful and he soon became wealthy after making numerous advances in medicinal drug manufacturing. Two of the early advances he pioneered were creating gelatin capsules to contain medicines and developing fruit flavorings. Eli Lilly and Company became one of the first pharmaceutical firms of its kind to staff a dedicated research department and put into place numerous quality-assurance measures.

Related Research Articles

Anatumomab mafenatox is a mouse monoclonal antibody studied for the treatment non-small cell lung cancer, which acts as a tumor-targeted superantigen.

Litoxetine (developmental code names SL 81-0385, IXA-001) is an antidepressant which was under clinical development for the treatment of depression in the early 1990s but was never marketed. It acts as a potent serotonin reuptake inhibitor (K_i for SERT = 7 nM) and modest 5-HT₃ receptor antagonist (K_i = 315 nM). It has antiemetic activity, and unlike the selective serotonin reuptake inhibitors (SSRIs), appears to have a negligible incidence of nausea and vomiting. The drug is structurally related to indalpine. Development of litoxetine for depression was apparently ceased in the late 1990s. However, as of March 2017, development of litoxetine has been reinitiated and the drug is now in the phase II stage for the treatment of urinary incontinence.

Teprotumumab (RG-1507) is an experimental human monoclonal antibody developed by Genmab and Roche. It binds to IGF-1R.

Dusigitumab is a human monoclonal antibody designed for the treatment of cancer. It binds to IGLF2. It was developed by MedImmune, which was acquired by AstraZeneca, using Xenomouse technology licensed from Abgenix.

Tovetumab is an anti-PDGFRa monoclonal antibody designed for the treatment of cancer. It was developed by MedImmune, and trialed for use in glioblastoma and non-small cell lung cancer. Development was discontinued in 2013.

AZD-5423 is a nonsteroidal glucocorticoid and phase II experimental drug being developed by AstraZeneca and disclosed at the spring 2013 American Chemical Society meeting in New Orleans to treat respiratory diseases and in particular chronic obstructive pulmonary disease.

Ontuxizumab is a humanized rabbit monoclonal antibody designed for the treatment of cancer. It binds to endosialin.

Apricoxib is an experimental anticancer drug. It is a COX-2 inhibitor which is intended to improve standard therapy response in molecularly defined models of pancreatic cancer. Development was abandoned in 2015 due to poor clinical trial results.

Remeglurant is a drug which acts as a selective antagonist of the mGlu₅ receptor. It is under development by Merz Pharmaceuticals for the treatment of drug-induced dyskinesia but no development has been reported since at least 2016.

ICI-164384, also known as N-n-butyl-N-methyl-11-(3,17β-dihydroxyestra-1,3,5 -trien-7α-yl)undecanamide, is a steroidal antiestrogen and a synthetic derivative of estradiol which is closely related to fulvestrant and was never marketed. It is a silent antagonist of the estrogen receptor (ER) with no intrinsic estrogenic activity and hence is a pure antiestrogen, unlike selective estrogen receptor modulators (SERMs) like tamoxifen. The drug was under development by AstraZeneca for the treatment of breast cancer but was discontinued in favor of fulvestrant, which is very similar to ICI-164384 but is more potent in comparison.

Fispemifene is a nonsteroidal selective estrogen receptor modulator (SERM) of the triphenylethylene group that was developed for the treatment of male hypogonadism but was abandoned and never marketed. It reached phase II clinical trials for this indication before development was terminated in March 2016. The drug failed to achieve statistical significance on key effectiveness endpoints in clinical trials and was discontinued by its developer for strategic reasons.

Cimlanod or CXL-1427 is an experimental drug for the treatment of acute decompensated heart failure. It was created by Cardioxyl Pharmaceuticals, which was acquired by Bristol-Myers Squibb. It is a nitric oxide donor.

Savolitinib is an experimental small molecule inhibitor of c-Met. It is being investigated for the treatment of cancer by AstraZeneca. It is in phase II clinical trials for adenocarcinoma, non-small cell lung cancer, and renal cell carcinoma.

Aripiprazole/sertraline is a combination formulation of sertraline (Zoloft), a selective serotonin reuptake inhibitor (SSRI), and aripiprazole (Abilify), an atypical antipsychotic, which is under development by Otsuka Pharmaceutical for the treatment of major depressive disorder (MDD). The drug combines serotonin reuptake inhibition and modulation of dopamine and serotonin receptors. As of July 2017, it is in preregistration in Japan for the treatment of MDD.

Nivacortol is a synthetic glucocorticoid corticosteroid which was never marketed.

Dagrocorat is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM) which was under development for the treatment of rheumatoid arthritis but was never marketed. It is described as a partial agonist and "dissociable" agonist of the glucocorticoid receptor. The drug reached phase I clinical trials prior to the discontinuation of its development. The C2α dihydrogen phosphate ester of dagrocorat, fosdagrocorat, was also under investigation, but its development was terminated as well.

Testosterone/dutasteride is a combination formulation of testosterone, an androgen, and dutasteride, a 5α-reductase inhibitor, which was under development by GlaxoSmithKline for the treatment of hypogonadism in men in the 2000s. It reached phase II clinical trials prior to the discontinuation of its development.

AGN-241751 is an orally active small-molecule NMDA receptor modulator which is under development for the treatment of major depressive disorder (MDD). It was originated by Naurex and was acquired by Allergan from Aptinyx in May 2018. Allergan is also developing the NMDA receptor modulators rapastinel and apimostinel for the treatment of MDD. Like apimostinel, AGN-241751 is intended as an oral follow-up compound to rapastinel. As of May 2018, the drug is in phase I clinical trials.

Nemorexant (developmental code name ACT-541468) is a dual orexin receptor antagonist (DORA) which was originated by Actelion Pharmaceuticals and is under development by Idorsia Pharmaceuticals for the treatment of insomnia. It acts as a selective dual antagonist of the orexin receptors OX₁ and OX₂. As of June 2018, nemorexant is in phase III clinical trials for the treatment of insomnia.

References

This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it.

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.

[1] "Statement On A Nonproprietary Name Adopted By The USAN Council: Flanvotumab" (PDF). American Medical Association.

[2] ttp://adisinsight.springer.com/drugs/800019264

[3] ttp://adisinsight.springer.com/drugs/800019264